<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82435">
  <stage>Registered</stage>
  <submitdate>29/11/2007</submitdate>
  <approvaldate>28/05/2008</approvaldate>
  <actrnumber>ACTRN12608000267358</actrnumber>
  <trial_identification>
    <studytitle>Cardiac Resynchronization Therapy Based Heart Failure Monitoring Study</studytitle>
    <scientifictitle>A nonrandomised trial on the safety and efficacy of performing intra-thoracic and intra-cardiac measurements, and realtime comparison with left atrial pressures using cardiac resynchronisation therapy in patients with heart failure.</scientifictitle>
    <utrn />
    <trialacronym>zLAP</trialacronym>
    <secondaryid>CRT based heart failure monitoring study
Ethics Ref:URB/07/10/052</secondaryid>
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients requiring the insertion of a Bi-ventricular pacemaker/defibrillator, for treatment of ventricular dyssynchrony and heart failure, will be offered the oppurtunity to participate in this trial. The sponsor will provide the PROMOTE device Model 3213, or later automatic internal cardiac defibrillator devices with similar functions. A HeartPOD (Left Atrial Pressure monitoring device) will be implanted at the same time. Research of the new features of the PROMOTE device to capture intra-thoracic and intra-cardiac electrical impedance measurements and left atrial pressures will be done. The completion of the trial will 
be when the 12th participant has had one year of follow-up.</interventions>
    <comparator>Uncontrolled. Validity of left atrial pressure (LAP) measurements will be checked at Right Heart Catheterisations.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and efficacy of performing intra-thoracic and intra-cardiac measurements, and left atrial pressures.</outcome>
      <timepoint>Months 1-3 : Clinical Observation period where therapy is managed by physician based on clinical criteria.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Therapy managed by patient per "DynamicRX"  based on twice daily left atrial pressure readings.</outcome>
      <timepoint>Months 4-6 : DynamicRX period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Therapy managed by physician based on clinical criteria and left atrial pressure</outcome>
      <timepoint>Months 4-6 : Titration period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age&gt;18 and &lt;=85;an approved indication for cardiac resynchronization therapy via pacemaker(CRT-P) or cardiac resynchronization therapy via defibrillator(CRT-D);may be a Homeostasis 1 trial participant;able and willing to participate as per the trial protocol.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Intractable Heart Failure or listed for cardiac transplantation; Acute Myocardial Infarction or Acute Coronary Syndrome; Recent surgery or (Percutaneous Coronary Intervention(PCI);Cerebrovascular Accident (CVA);Transient Ischaemic Attack(TIA);Pulmonary Embolus (PE);Deep Vein Thrombosis(DVT).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Potential participants are consented. All participants will receive a defibrillator and a study device (left atrial pressure measurement device)</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/01/2008</anticipatedstartdate>
    <actualstartdate>30/01/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>22/06/2010</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>9</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St Jude Medical</primarysponsorname>
    <primarysponsoraddress>15900 Valley View Court
Sylmar, CA 91342</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>St Jude Medical</fundingname>
      <fundingaddress>15900 Valley View Court
Sylmar, CA 91342</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>St Jude Medical</fundingname>
      <fundingaddress>15900 Valley View Court
Sylmar, CA 91342</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Christchurch Hospital</sponsorname>
      <sponsoraddress>Riccarton Ave, 
Christchurch</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A single centre study collecting and analyzing intra-thoracic and intra-cardiac electrical impedance measurements, intra-cardiac conduction time delays, and the left ventricular evoked response signal parameters from the St Jude Medical Cardiac Resynchronization Therapy (SJM CRT) device in a heart failure population with an implanted left atrial pressure sensor.</summary>
    <trialwebsite />
    <publication>Abstract 12281: Impedance is an Unreliable Surrogate for Left Atrial Pressure in Ambulatory
Patients with Heart Failure Richard Troughton1; Wandy Chan1; Iain Melton2; Ian Crozier2; Dan Gutfinger3; Fujian Qu3; Neal Eigler3; Spencer Rosero4; Leway Chen4; Philip Adamson5; Mark Harvey6; Maria Costanzo7; Apoor Gami8; William T Abraham9</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>current study completed as LAPTOP study completed early. No results available yet.  (the LAPTOP study is the randomised study comparing the clinical benefits of the heartPOD device compared with normal treatment)
</publicnotes>
    <ethicscommitee>
      <ethicname>Upper South B Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health, 4th Floor, 250 Oxford Tce
PO Box 3877, Christchurch</ethicaddress>
      <ethicapprovaldate>12/11/2007</ethicapprovaldate>
      <hrec>URB/07/10/052</hrec>
      <ethicsubmitdate>8/10/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Richard Troughton</name>
      <address>Cardiology Department
2nd Floor Parkside West
Christchurch Hospital</address>
      <phone>+64 3 364 1096</phone>
      <fax>+64 3 3641120</fax>
      <email>richard.troughton@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Catherine Cruickshank</name>
      <address>Cardiology Clinical Trials Unit
2nd Floor Parkside West
Christchurch Hospital</address>
      <phone>+64 3 364 1096</phone>
      <fax>+64 3 378 6378</fax>
      <email>Catherine.cruickshank@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Cruickshank </name>
      <address>Cardiology Clinical Trials Unit
2nd Floor Parkside West
Christchurch Hospital</address>
      <phone>+64 3 364 1096</phone>
      <fax>+64 3 378 6378</fax>
      <email>Catherine.cruickshank@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Richard Troughton</name>
      <address>Cardiology Department
Christchurch Hospital
Private Bag 4710
Christchurch 8140</address>
      <phone>+64 3 3640 640</phone>
      <fax />
      <email>richard.troughton@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>